Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

被引：11
|
作者：
Byrd, John C.
Jones, Jeffrey Alan
Furman, Richard R.
Stephens, Deborah Marie
Devereux, Steve
Brown, Jennifer R.
Hillmen, Peter
Hamdy, Ahmed M.
Fardis, Maria
Tawashi, Manal
Wang, Min Hui
Patel, Priti
Mittag, Diana
Krantz, Fanny
Rothbaum, Wayne
Izumi, Raquel
O'Brien, Susan Mary
Wierda, William G.
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] NHS Fdn Trust Denmark Hill, Coll Hosp, London, England
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] St James Univ Hosp, Leeds, W Yorkshire, England
[7] Acerta Pharma, Santa Cruz, CA USA
[8] Pharmacycl Inc, Sunnyvale, CA USA
[9] Acerta Pharma, Redwood City, CA USA
[10] Acerta Pharma, San Carlos, CA USA
[11] Univ Calif Irvine, Irvine, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7521
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Eichhorst, Barbara
    Ghia, Paolo
    Kater, A. P.
    Li, Jianyong
    Khurana, Sudha
    Elhamy, Mostafa
    Wang, Min Hui
    Seymour, John F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S221 - S222
  • [42] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [43] Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)
    Pleyer, Christopher
    Cohen, Jeffrey
    Soto, Susan
    Ali, Mir
    Ahn, Inhye E.
    Nierman, Pia
    Valdez, Janet
    Lotter, Jennifer
    Superata, Jeanine
    Tian, Xin
    Wiestner, Adrian
    Sun, Clare
    BLOOD, 2019, 134
  • [44] Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia Beyond Ibrutinib
    Lasica, Masa
    Tam, Constantine S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 761 - 773
  • [45] Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease
    Woyach, Jennifer A.
    Stefanovski, Matthew R.
    Goettl, Virginia
    Ruppert, Amy S.
    Smucker, Kelly A.
    Smith, Lisa L.
    Dubovsky, Jason A.
    Towns, William H.
    MacMurray, Jessica
    Davis, Melanie E.
    Mao, Yicheng
    Chang, Betty Y.
    Buggy, Joseph J.
    Byrd, John C.
    Johnson, Amy J.
    BLOOD, 2012, 120 (21)
  • [46] Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy
    George, Binsah
    Chan, Kok Hoe
    Rios, Adan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
    Byrd, J. C.
    Blum, K. A.
    Burger, J. A.
    Coutre, S. E.
    Sharman, J. P.
    Furman, R. R.
    Flinn, I. W.
    Grant, B. W.
    Richards, D. A.
    Zhao, W.
    Heerema, N. A.
    Johnson, A. J.
    Izumi, R.
    Hamdy, A.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia
    Banerji, V
    Aw, A.
    Robinson, S.
    Doucette, S.
    Christofides, A.
    Sehn, L. H.
    CURRENT ONCOLOGY, 2020, 27 (06) : E645 - E655
  • [49] Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Lymphoma
    Varma, Gaurav
    Johnson, Tyler P.
    Advani, Ranjana H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (07) : 543 - 554
  • [50] Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
    Tuncer, Hande H.
    Ghosh, Nilanjan
    Fleury, Isabelle
    Leslie, Lori A.
    Manzoor, Beenish S.
    Lamanna, Nicole
    Eyre, Toby A.
    Hill, Brian T.
    Brown, Jennifer R.
    Sinai, Wendy
    Coombs, Catherine C.
    Ujjani, Chaitra
    Roeker, Lindsey E.
    Emechebe, Nnadozie
    Barr, Paul M.
    Davids, Matthew S.
    Martinez-Calle, Nicolas
    Rhodes, Joanna M.
    Lansigan, Frederick
    Pearson, Laurie
    Choi, Yun
    Schuster, Stephen J.
    Skarbnik, Alan P.
    Fakhri, Bita
    Coyle, Michael
    Stephens, Deborah M.
    Thompson, Meghan C.
    Jensen, Christopher E.
    Marx, Steven E.
    Jawaid, Dureshahwar
    Schuh, Anna
    Pivneva, Irina
    Watson, Talissa
    Guerin, Annie
    Shadman, Mazyar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S357 - S358
12345